Recombinant Proteins Market worth $3.2 billion by 2028 | MarketsandMarkets Trademark

The global recombinant proteins market, valued at US$2.1B in 2022, is forecasted to grow at a 7.2% CAGR, reaching US$2.2B by 2023 and US$3.2B by 2028.
Recombinant Proteins market [https://www.marketsandmarkets.com/Market-Reports/recombinant-proteins-market-70095015.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] in terms of revenue was estimated to be worth $2.2 billion in 2023 and is poised to reach $3.2 billion by 2028, growing at a CAGR of 7.2% from 2023 to 2028 according to a latest report published by MarketsandMarkets Trademark . Market growth is largely driven by increasing prevalence of chronic diseases, increased demand for biologics and biosimilars due to patent expirations, escalating government support for research and development in life sciences and rising demand for personalized medicine.

Based on product, the global recombinant proteins market is segmented into growth factors and chemokines, immune response proteins, structural proteins, membrane proteins, kinase proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. The growth factors and chemokines segment accounted for the largest share of the market in 2022. The segment dominant the market owing various factors such as diversified application of growth factors for various cellular processes such as cell growth, proliferation, differentiation and for the research in chemotaxis, neurobiology, wound healing, immunology, cancer, viral diseases, cell culture, and stem cell research.

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=70095015 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=70095015&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Based on application, the global recombinant proteins market is segmented into drug discovery & development, biopharmaceutical production, research, diagnostics and other applications. In 2022, the drug discovery & development segment accounted for the largest share of the recombinant proteins market. The largest share can be attributed to the growing importance of recombinant proteins in small molecule drug discovery programs and developing new compounds that impact the function of disease-associated proteins or their respective protein-protein interactions.

Based on host cell, the global recombinant proteins market is segmented into mammalian systems, insect cells, & fungi, bacterial cells and other host cell. In 2022, the bacterial cells segment accounted for the largest share of the recombinant proteins market. The largest share is due to factors such as well-characterized genetics, ease of manipulation, and cost-effectiveness compared to other systems.

Based on end user, the global recombinant proteins market is segmented into, pharmaceutical & biopharmaceuticals companies, biotechnology companies, academic & research institutes, contract research organizations (CROs) and other end users. In 2022, pharmaceutical & biopharmaceuticals companies segment accounted for the largest share of the market. The key factor of driving the growth of this market segment can be attributed to the utilization of recombinant proteins in the identification of prognostic, predictive, and diagnostic markers and quantifying biomarkers during drug discovery & development.

Based on the region, the global recombinant proteins market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. In 2022, North America accounted for the largest share in the recombinant proteins market, Europe is the second largest region in 2022. The dominance in the market can be attributed to to the rising acceptance of personalized medicine, increasing academic & government investments in diagnostic research and active government support. The Asia Pacific market is expected to register the highest CAGR of 7.8% during the forecast period. In 2022, the growth of the market is driven by the increasing government intitaives for life sciences research, rising investment for academic collaboration and rising prevalence of chronic diseases in this region.

Buy a Recombinant Proteins Industry Report (406 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=70095015 [https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=70095015&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Recombinant Proteins market major players covered in the report, such as:

* Bio-Techne (US)
* Thermo Fisher Scientific Inc. (US)
* Merck KGaA (Germany)
* Abcam plc (UK)
* Abnova Corporation (Taiwan)
* Biolegend Inc (US)
* Bio-Rad Laboratories, Inc. (US)
* BPS Bioscience, Inc. (US)
* Enzo Biochem, Inc. (US)
* GenScript (China)
* Miltenyi Biotec B.V. & Co. KG (Germany)
* Proteintech Group, Inc. (US)
* Sino Biological Inc. (China)
* ACROBiosystems Group (US)
* Aviva Systems Biology Corporation (US)
* Sartorius CellGenix GmbH (Germany)
* Icosagen (US)
* Neuromics (US)
* ProSpec-Tany Technogene Ltd (Israel)
* ProteoGenix S.A.S (France)
* RayBiotech Inc (US)
* Laurus Bio (India)
* Stemcell Technologies (Canada)
* StressMarq Biosciences Inc (Canada)
* United States Biological (US)
* and Among Others

This report categorizes the recombinant proteins market into the following segments and subsegments:

By Product

* Growth Factors and Chemokines

* Interferons (IFNs)
* Interleukins (ILs)
* Other growth factors & chemokines

* Immune Response Proteins
* Structural Proteins
* Membrane Proteins
* Kinase Proteins
* Regulatory Proteins
* Recombinant Metabolic Enzymes
* Adhesion Molecules and Receptors
* Other Recombinant Proteins

By Application

* Drug Discovery & Development

* Biologics
* Vaccines
* Cell & Gene Therapy

* Biopharmaceutical Production

* Research

* Academic Research
* Biotechnology Research

* Diagnostics
* Other Applications
* By Host cell
* Mammalian Systems
* Insect Cells
* Yeast & Fungi
* Bacterial Cells
* Other host cell

By End User

* Pharmaceutical & Biopharmaceutical Companies
* Biotechnology Companies
* Academic Research Institutes
* Contract Research Organizations
* Other End Users

By Region

* North America

* US
* Canada

* Europe

* Germany
* UK
* France
* Italy
* Spain
* Rest of Europe (ROE)

* Asia Pacific

* Japan
* China
* India
* South Korea
* Rest of Asia Pacific

* Latin America

* Brazil
* RoLATAM

* Middle East

* GCC Countries
* Rest of Middle East

* Africa

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=70095015 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=70095015&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=recombinant-proteins-market-worth-32-billion-by-2028-marketsandmarkets]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/recombinant-proteins-market-70095015.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.